SEL-212
Selecta Biosciences
[]
selecta biosciences announces presentation of data from phase 3 dissolve program of sel-212 in chronic refractory gout during late-breaking session at the eular 2023 european congress of rheumatology 
The latest news about the biotech and pharmaceutical industy.